Evaluation of synthetic peptides of WbSXP-1 for the diagnosis of human lymphatic filariasis

Pandiaraja, Pandurangan; Arunkumar, Chakkaravarthy; Hoti, S.L.; Rao, D. N.; Kaliraj, Perumal

doi:10.1016/j.diagmicrobio.2010.07.015

Cited by 19 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This property could be based on the molecular size, rigidity, chemical complexity, interaction with B-cell receptors, or MHC and activation of helper T cells [92]. The p1 proved to be an antigen that is recognized by the IgG Ab from immunized rabbits and infected individuals, using the methodology reported for other peptides [93][94][95]. IgG antibodies in human serum, mainly the IgG2 isotype, demonstrate that clinical or subclinical infections with the influenza virus induced IgG to the peptide.…”

Section: Discussionmentioning

confidence: 99%

A continuous peptide epitope reacting with pandemic influenza AH1N1 predicted by bioinformatic approaches

et al. 2015

View full text Add to dashboard Cite

Computational identification of potential epitopes with an immunogenic capacity challenges immunological research. Several methods show considerable success, and together with experimental studies, the efficiency of the algorithms to identify potential peptides with biological activity has improved. Herein, an epitope was designed by combining bioinformatics, docking, and molecular dynamics simulations. The hemagglutinin protein of the H1N1 influenza pandemic strain served as a template, owing to the interest of obtaining a scheme of immunization. Afterward, we performed enzyme-linked immunosorbent assay (ELISA) using the epitope to analyze if any antibodies in human sera before and after the influenza outbreak in 2009 recognize this peptide. Also, a plaque reduction neutralization test induced by virus-neutralizing antibodies and the IgG determination showed the biological activity of this computationally designed peptide. The results of the ELISAs demonstrated that the serum of both prepandemic and pandemic recognized the epitope. Moreover, the plaque reduction neutralization test evidenced the capacity of the designed peptide to neutralize influenza virus in Madin-Darby canine cells.

show abstract

Section: Discussionmentioning

confidence: 99%

A continuous peptide epitope reacting with pandemic influenza AH1N1 predicted by bioinformatic approaches

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A number of immunoassays using a variety of different filarial Ags have been proposed for use as surveillance tools in LF; these include Bm14/BmSXP-1 [12], BmR1 [13], WbSXP-1 [14], and Bm33 [15]. The sensitivity of these assays has generally been high but limited specificity with respect to non-LF causing filariae (Ov, Ll, Mansonella spp. )…”

Section: Introductionmentioning

confidence: 99%

Identification of Wb123 as an Early and Specific Marker of Wuchereria bancrofti Infection

Kubofcik¹,

Fink²,

Nutman

2012

PLoS Negl Trop Dis

View full text Add to dashboard Cite

BackgroundThe current antibody tests used for monitoring in lymphatic filariasis (LF) elimination programs suffer from poor specificity because of the considerable geographical overlap with other filarial infections such as Loa loa (Ll), Onchocerca volvulus (Ov), and Mansonella perstans (Mp).MethodsUsing bioinformatics to assemble into contigs 2048 expressed sequence tags (ESTs) from the L3 infective larvae of W. bancrofti (Wb), these were next assessed for homology to known proteins and nucleotides and to similar assemblies of L3 larval ESTs of B. malayi (Bm – n = 5068), Ov (n = 4166), and Ll (n = 3315). Nineteen potential L3- and Wb- and/or Bm-specific antigens were identified. Sixteen of the 19 antigens could be expressed as fusion proteins with Renilla luciferase (Ruc); these were used in a rapid Luciferase Immunopreciptation System (LIPS) assay.ResultsOne of the 16 expressed antigens (Wb123) was both highly immunogenic and specific for Wb. Using Wb123-based IgG and IgG4 LIPS assays on well-defined sera from normal North Americans and those infected exclusively with intestinal helminths, we could detect all of the Wb-infected individuals (from diverse geographic regions) with 100% sensitivity and 100% specificity. Using sera from exclusively Ll-infected, Ov-infected Mp-infected or Bm-infected subjects as the negative comparator, the sensitivities were between 98–100% and the specificities ranged between 84–100% (for IgG anti-Wb123) and between 98–100% (for IgG4 anti-Wb123). Blinded assessments using panels of sera from various Wb-, Bm- or non-Wb helminth-infected subjects demonstrated equally high degrees of sensitivity and specificity.SignificanceWe have identified a Wb-encoded antigen that can be used both as a rapid, high throughput tool to diagnose individual Wb infections and as a sensitive method for early detection of recrudescent infections in areas of control and for mapping new areas of Wb transmission.

show abstract

“…A number of serological Ab assays based on filarial Ags have been proposed for use as surveillance tools, including Bm14 [9], BmR1 and BmSXP [10], WbSXP-1 [11], and Bm33 [12]. The most widely field tested assays have used Bm14 Ag in ELISA [5], [8], [9], [13], [14] or other formats [7].…”

Section: Introductionmentioning

confidence: 99%

Antibody to the Filarial Antigen Wb123 Reflects Reduced Transmission and Decreased Exposure in Children Born following Single Mass Drug Administration (MDA)

et al. 2012

View full text Add to dashboard Cite

BackgroundAntibody (Ab) to the Wuchereria bancrofti (Wb) infective larval (L3) antigen Wb123, using a Luciferase Immunoprecipitation System (LIPS) assay, has been shown to be a species-specific, early marker of infection developed for potential use as a surveillance tool following transmission interruption post mass drug administration. To examine its usefulness in a single filarial-endemic island assessed at two time points with markedly different levels of transmission, Ab to Wb123 was measured in sera collected from subjects from Mauke, Cook Islands in 1975 (no previous treatment) and 1992 (5 years after a one time island-wide treatment with diethylcarbamazine [DEC]).FindingsBetween 1975 and 1992, Wb transmission decreased dramatically as evidenced by reduced prevalences of microfilariae (31% vs. 5%) and circulating Ag (CAg, 49% vs. 16%). Age specific prevalence analysis showed a dramatic reduction in Wb123 Ab positivity from 54% (25/46) in 1975 to 8% (3/38) in 1992 in children 1–5 years (p<0.0001), reflecting the effects of single-dose treatment five years earlier. By 1992, Wb123 Ab prevalence in children 6–10 years had fallen from 75% (42/56) in 1975 to 42% (33/79) consistent with a lower cumulative transmission potential. In the whole population, Wb123 seropositivity decreased from 86% to 60% between 1975 and 1992. In CAg+ subjects the levels of Wb123 Ab were indistinguishable between the 2 time points but differed in those who were CAg− (p<0.0001). In paired sample analysis, individuals who were CAg+ in 1975 but became CAg− in 1992 had significantly lower Ab levels in 1992 (p<0.0001), with 9/40 (23%) becoming seronegative for Wb123.ConclusionsThe relationship between reduction in Wb123 Ab prevalence and the reduction of transmission, seen most clearly in young children, strongly advocates for the continuing assessment and rapid development of Wb123 as a surveillance tool to detect potential transmission of bancroftian filariasis in treated endemic areas.

show abstract

Evaluation of synthetic peptides of WbSXP-1 for the diagnosis of human lymphatic filariasis

Cited by 19 publications

References 22 publications

A continuous peptide epitope reacting with pandemic influenza AH1N1 predicted by bioinformatic approaches

A continuous peptide epitope reacting with pandemic influenza AH1N1 predicted by bioinformatic approaches

Identification of Wb123 as an Early and Specific Marker of Wuchereria bancrofti Infection

Antibody to the Filarial Antigen Wb123 Reflects Reduced Transmission and Decreased Exposure in Children Born following Single Mass Drug Administration (MDA)

Contact Info

Product

Resources

About